CLLS Earnings

CLLS reported its FY2025Q3 earnings on 2025-11-07, showcasing a revenue of 37.00M against an estimate of 10.00M, resulting in a 288.62% surprise. The EPS was 0, surpassing the expected 0 by 0% . The stock experienced a 11.29% price change on the earnings day and a 11.91% change over the next five days, reflecting market reactions to the results.

Following CLLS's FY2025Q3 earnings announcement on 2025-11-07, the stock price moved by 11.29% on the day of the release. Over the subsequent five days, it saw a 11.91% change. Historically, CLLS's stock price tends to shift by an average of -3.79% in the 10 days leading up to earnings and +7.53% in the 10 days following, providing insight into potential market.

For , analysts estimate CLLS’s annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 45.02% and EPS estimates Revise Upward by 22.86% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CLLS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 45.02%, while EPS estimates moved Revise Upward by 22.86% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CLLS's stock price typically moves by -3.79% in the 10 days before its earnings and +7.53% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call summary presents a mixed picture. Financials show a cash decrease, but the cash runway is secure until 2027. Product development updates are promising, with regulatory alignment and no barriers to Phase II trials. However, uncertainties remain, such as the Servier arbitration decision and lack of milestone payment details. The Q&A session did not reveal major negative sentiments but highlighted cautious optimism from management. The overall sentiment is neutral, as positive product development is offset by financial and legal uncertainties.